Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

BACKGROUND: This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study. METHODS: This randomised...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Feng-Cai, Guan, Xu-Hua, Li, Yu-Hua, Huang, Jian-Ying, Jiang, Tao, Hou, Li-Hua, Li, Jing-Xin, Yang, Bei-Fang, Wang, Ling, Wang, Wen-Juan, Wu, Shi-Po, Wang, Zhao, Wu, Xiao-Hong, Xu, Jun-Jie, Zhang, Zhe, Jia, Si-Yue, Wang, Bu-Sen, Hu, Yi, Liu, Jing-Jing, Zhang, Jun, Qian, Xiao-Ai, Li, Qiong, Pan, Hong-Xing, Jiang, Hu-Dachuan, Deng, Peng, Gou, Jin-Bo, Wang, Xue-Wen, Wang, Xing-Huan, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836858/
https://www.ncbi.nlm.nih.gov/pubmed/32702299
http://dx.doi.org/10.1016/S0140-6736(20)31605-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836858/
https://www.ncbi.nlm.nih.gov/pubmed/32702299
http://dx.doi.org/10.1016/S0140-6736(20)31605-6

Ejemplares similares